Abbott实验室达到了2025年Q4的预期收入水平,提高了2026年的指导意见,并看到内幕人员通过机构购买进行销售。 Abbott Labs met earnings expectations in Q4 2025, raised 2026 guidance, and saw insider sales with institutional buying.

Abbott实验室报告说,2025年第四季度的收益为每股1.50美元,达到了预期水平,收入为114.6亿美元,略低于估计数,但逐年增长4.4%。 Abbott Laboratories reported fourth-quarter 2025 earnings of $1.50 per share, meeting expectations, with revenue of $11.46 billion, slightly below estimates, but up 4.4% year-over-year. 该公司将其2026年全年收入指导提高到每股5.55至5.80美元,其第一季度展望提高到1.12至1.18美元。 The company raised its 2026 full-year earnings guidance to $5.55–$5.80 per share and its first-quarter outlook to $1.12–$1.18. 分析师维持“中度购买”共识,目标价格为136.16美元。 Analysts maintain a "moderate buy" consensus with a $136.16 target price. 该股票截至2026年3月2日交易约115.58美元,市场上限为1 910亿美元,股息收益为2.3%,在诊断、医疗设备、营养和药品方面在全球范围运作。 The stock, trading around $115.58 as of March 2, 2026, has a market cap of $191 billion, a 2.3% dividend yield, and operates globally in diagnostics, medical devices, nutritionals, and pharmaceuticals. 内部销售包括执行副总裁Mary K. Moreland和John A. Jr. McCoy,而像Focus伙伴财富和Mercer全球顾问公司这样的机构投资者则增加了他们的利害关系。 Insider sales included executive vice presidents Mary K. Moreland and John A. Jr. McCoy, while institutional investors like Focus Partners Wealth and Mercer Global Advisors increased their stakes.